REG - Verici Dx PLC - Update on funding to accelerate commercial growth

Verici DxAnnouncement

11/06/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250611:nRSK2863Ma&default-theme=true

RNS Number : 2863M  Verici Dx PLC  11 June 2025

 

Verici Dx plc

("Verici Dx" or the "Company")

 

Update on funding to accelerate commercial growth

 

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for
organ transplant, provides an update on its plans to raise funds to enable the
Company to accelerate commercial growth and support the scale up of Tutivia™
revenues, having secured Medicare Coverage for Tutivia™, as announced in
April 2025
(https://www.londonstockexchange.com/news-article/VRCI/verici-receives-medicare-coverage-for-tutivia/16984309)
.

 

Further to the announcement on 7 April 2025
(https://www.londonstockexchange.com/news-article/VRCI/significant-test-growth-with-medicare-pending/16976543)
, the Company is proposing to carry out an equity fundraising (the
"Fundraising") to extend the Company's cash runway and enable it to achieve
its commercial objectives for Tutivia™, its diagnostic test for acute
rejection. The Company is working with its advisers and has received positive
indications of support from a number of existing and new institutional and
other investors. The Fundraising, which if completed, would extend the
Company's cash runway, would provide growth finance to accelerate commercial
roll-out and support the scale up of Tutivia™ revenues. The Company remains
on track to deliver $3.2 million in Tutivia™ revenues for FY 2025, in-line
with market expectations.

 

The size and structure of the Fundraising is yet to be determined by the
Board, however it is anticipated to include a placing as well as the
opportunity for participation by all existing shareholders via a retail offer.
The allotment authorities that were granted at the General Meeting held on 27
May 2025 will be sufficient for the proposed Fundraising and so the Company
would not need to obtain further authority to issue and allot new Ordinary
Shares on a non-pre-emptive basis. A further update will be provided by the
Company before the end of June.

 

As at 31 May 2025 the Company held a cash position of $1.04 million,
reflecting receipt of the expected $750k milestone payment from Thermo Fisher,
due under the commercial contract for the PTRA (Pre Transplant Risk
Assessment) test. This and the expected receivables from the Medicare Coverage
extends the Company's current cash runway, beyond previous expectations, to at
least the end of July 2025.

 

2024 Annual Results

 

The Company is currently working with its auditors to ensure that it announces
its audited results for the year ended 31 December 2024 by the end of June as
planned.

 

 

 Verici Dx plc                                 www.vericidx.com (https://vericidx.com/)

 Sara Barrington, CEO                          Via Walbrook PR

 Singer Capital Markets (Nominated Adviser and Broker)                      Tel: +44 (0)20 7496 3000
 Phil Davies / Sam Butcher

 Walbrook PR (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com
 Alice Woodings / Paul McManus                 Mob: +44 (0)7407 804 654 / +44 (0)7980 541 893

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDSFFFWSEISEDM